Both TEGSEDI and WAYLIVRA are legacy assets that were originally brought to the EU market via an Ionis subsidiary, Akcea ...

The goal is to develop a disease modifying treatment that stops or slow down the progression of alpha-synucleinopathies e.g. Parkinson's disease and MSA. BioArctic's phase 2a study EXIST with ...

“Synucleinopathies such as dementia with Lewy bodies and Parkinson’s disease represent a significant unmet medical need due to the lack of any effective disease-modifying treatments,” said ...

Sanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson's disease, licensing a bispecific antibody from South Korea's ABL Bio in a deal that could ...

Sanofi ADS has moved -0.7% over the last year, and the S&P 500 logged a change of 11.9% SNY has an average analyst rating of ...

Research into extracellular vesicles (EVs) biology has increased considerably over the past decade, posing manifold questions regarding their involvement in homeostatic and pathological processes. EVs ...

Alpha-synuclein in disease pathogenesis Research studies strongly support a role for alpha-synuclein in the pathogenesis of Parkinson's disease, dementia with Lewy bodies and multiple systems atrophy.

The Lancet Neurology, Marialuisa Quadri and colleagues1 recently identified variants in LRP10 in families with autosomal dominant Parkinson's disease and dementia with Lewy bodies. Nine rare LRP10 ...

The Lancet Neurology, Marialuisa Quadri and colleagues1 recently identified variants in LRP10 in families with autosomal dominant Parkinson's disease and dementia with Lewy bodies. Nine rare LRP10 ...